Summary
Today, many measures of disease (and disease outcomes) are based largely on input from clinicians. As such they do not fully capture patients’ own experiences of the disease and its impact on their lives.
The aim of H2O is to create ‘health outcomes observatories’ that will amplify the patient voice both in their own healthcare and in healthcare systems more broadly.
The health outcomes observatories will work by providing patients with digital tools, including an app, to report their health outcomes in a standardised way. Patients will always maintain control of their own data and will decide who can access it. At one level, the information will help clinicians and patients to make better decisions on their care.
Meanwhile, the data will be anonymised and tracked so that individual patients and their clinicians can compare their progress with other patients with similar health issues. This aggregated data could also form the basis of research into new, innovative, evidence-based treatments.
The project will focus on setting up health outcomes observatories in four countries (Germany, Spain, the Netherlands, and Austria) covering three disease areas: diabetes, inflammatory bowel disease, and cancer. In the longer term, the project hopes that more observatories, covering a wider range of disease areas, will open up across Europe.
Achievements & News
September 2022
IMI project H2O has launched its first health outcomes observatories, in the Netherlands, Spain and now Austria.
April 2025
How can IHI and IMI projects harness the opportunities posed by real-world data and AI to make Europe a leader...
February 2025
IMI and IHI projects provide a neutral platform where public and private datasets can be shared within a secure environment...
October 2023
Patients who sign the agreement can both measure their own outcomes and control how their data is used for research.
Participants
Show participants on mapUniversities, research organisations, public bodies, non-profit groups
- Abbvie Inc, North Chicago Il, United States
- Astrazeneca AB, Sodertaelje, Sweden
- Breakthrough T1d, New York, United States
- Charite - Universitaetsmedizin Berlin, Berlin, Germany
- Eli Lilly And Company LTD, Basingstoke, United Kingdom
- Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Forum Des Patients Europeens, Brussels / Bruxelles, Belgium
- H2o Pan European Observatory, Nordhavn, Denmark
- Health Outcomes Observatory - Germany (H2o) E.V, Berlin, Germany
- Health Outcomes Observatory Nederland (H2o-Nl), Rotterdam, Netherlands
- Institut Catala De La Salut, Barcelona, Spain
- Katholieke Universiteit Leuven, Leuven, Belgium
- King'S College London, London, United Kingdom
- Medizinische Universitaet Wien, Wien, Austria
- Novartis Pharma AG, Basel, Switzerland
- Pfizer Limited, Sandwich, United Kingdom
- Region Stockholm, Stockholm, Sweden
- Sanofi-Aventis Recherche & Developpement, Gentilly, France
- Stichting Integraal Kankercentrum Nederland, Utrecht, Netherlands
- Takeda Pharmaceuticals International AG, Glattpark, Switzerland
- Teamit Research SL, Barcelona, Spain
- The European Institute For Innovation Through Health Data, Oosterzele, Belgium
- The Hyve BV, Utrecht, Netherlands
- Trial Nation, Copenhagen, Denmark
- Universita Vita-Salute San Raffaele, Milano, Italy
Third parties
- Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
- Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain
Participants | |
---|---|
Name | EU funding in € |
Charite - Universitaetsmedizin Berlin | 1 191 508 |
Erasmus Universitair Medisch Centrum Rotterdam | 1 279 661 |
Forum Des Patients Europeens | 450 413 |
H2o Pan European Observatory | 54 688 |
Health Outcomes Observatory - Germany (H2o) E.V | 2 688 |
Health Outcomes Observatory Nederland (H2o-Nl) | 4 688 |
Institut Catala De La Salut | 4 688 |
Katholieke Universiteit Leuven | 458 188 |
King'S College London | 680 000 |
Medizinische Universitaet Wien | 2 106 724 |
Region Stockholm | 548 375 |
Stichting Integraal Kankercentrum Nederland | 563 813 |
Teamit Research SL | 600 062 |
The European Institute For Innovation Through Health Data | 564 625 |
The Hyve BV | 536 250 |
Universita Vita-Salute San Raffaele | 333 063 |
Third parties | |
Name | Funding in € |
Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca | 1 016 008 |
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio) | 81 250 |
Total Cost | 10 476 692 |